Vendor Intelligence Report: Shanghai JinBei Chemical Technology

Executive summary

Across 31 Finnrick lab tests, Shanghai JinBei Chemical Technology records 26 pass results and 5 failures, an 84% overall pass rate. The testing record is real enough to separate JinBei from a simple non-delivery shop, but it is product-specific rather than broadly reassuring. GHK-Cu is the cleanest line in the current data; Retatrutide is more defensible than Tirzepatide among the GLP-1 products, while both require lot verification and label-to-COA matching rather than trust in the catalog.

The deeper risk is not identity failure in the lab; it is control and traceability. Finnrick's records include genuine, test-passing peptides, yet the full file also documents unlabeled or no-batch vials and scores that compress under stricter grading. That narrows JinBei's practical use case to selective purchasing with independent testing.

Corporate records and web artifacts tell a different story from the manufacturer narrative. SGS-backed marketplace registration and Chinese registry traces point to a young Shanghai trading entity, while the public site claims factory scale, ISO systems, and global reach. The About page carries a retained copy-paste reference to another supplier, and two Global Sources accounts tied to the same registration trail present conflicting company scale.

The report also follows risk outside the peptide vial: a dead secondary domain, brand-confusion surfaces, sales personas, wire and crypto-heavy payment rails, reported Kingtrans freight-forwarder routing, and website materials that market precursor chemistry beside peptides and other high-risk pharmaceuticals. The result is not a blanket avoid verdict, but a transaction-specific warning: GHK-Cu is the strongest tested case; GLP-1 orders need tighter verification, smaller exposure, and written reship terms.

Inside the full report:

• Per-product pass/fail rates, spark-grid trajectories, and methodology-divergence charts for all 3 tested products
• SGS-backed marketplace profiles and Chinese registry-trail analysis of the trading-company identity
• Side-by-side About-page plagiarism exhibits using JinBei's page and the source supplier's original text
• WHOIS, DNS, certificate-transparency, and dead-domain assessment for jinbeichem.cn and elipeptide.com
• Catalog-risk analysis covering precursor-chemistry articles and high-risk pharmaceutical categories
• Shipping, payment, customer-thread, and CBP-style seizure-exposure review, including Kingtrans routing evidence

Risk assessment

• Fabricated manufacturer identity and inconsistent registration claims — high: Copied Quanjinci About text, trading-company registration, unsupported factory and ISO claims, and conflicting Global Sources capitalization weaken claims of direct manufacturing control.
• Peptide consistency risk — Retatrutide and Tirzepatide — medium: Retatrutide is 81.53% across 12 tests and Tirzepatide is 78.25% across 13 tests; both have failures and require lot verification rather than blanket trust.
• Unlabeled-vial and batch-traceability risk — high: Multiple submitted vials reportedly lacked labels or batch IDs, preventing reliable COA matching, recall, or adverse-event trace-back.
• Regulated-chemistry portfolio risk — high: JinBei marketed CAS 69673-92-3 as a replacement for precursor CAS 1451-82-7 and lists high-risk pharmaceuticals beside peptides.
• Customs seizure and payment-recourse risk — high: Reported Kingtrans forwarding, wire/Western Union/crypto payment rails, and CBP action against similar peptide-import schemes leave buyers exposed if shipments are seized or disputed.
• Post-payment fulfillment dispute risk — medium: Multiple Reddit/forum threads report tracking disputes, delays, incomplete orders, or silence after payment; allegations are not individually adjudicated but recur across sources.
• Brand-confusion and official-channel verification risk — medium: Dead elipeptide.com listing, unrelated Jinbei/Shandong signals, name variants, and no authoritative channel list make misdirection harder to rule out.